VBI Vaccines (OTCPK:VBIV.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

VBIV.Q Stoklara Genel Bakış

Ticari aşamada bir biyofarmasötik şirketi olan VBI Vaccines Inc. immüno-onkoloji ve bulaşıcı hastalıkları tedavi etmek için aşılar geliştirmekte ve satmaktadır.

Şirket hakkında

VBIV.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Does not have a meaningful market cap ($488K)

Highly volatile share price over the past 3 months

Negative shareholders equity

Earnings have declined by 17.4% per year over past 5 years

+ 1 daha fazla risk

VBI Vaccines Inc. Rakipler

TRACON Pharmaceuticals

OTCPK:TCON

US$357.8k

IPI Legacy Liquidation Co

OTCPK:IMPL.Q

US$358.5k

Cyclacel Pharmaceuticals

NasdaqCM:CYCC

US$2.0m

Theralink Technologies

OTCPK:THER

US$615.1k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti VBI Vaccines
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.017
52 Haftanın En Yüksek Seviyesi	US$1.35
52 Haftanın En Düşük Seviyesi	US$0.013
Beta	2.11
11 Aylık Değişim	-5.56%
3 Aylık Değişim	-97.73%
1 Yıllık Değişim	-97.23%
33 Yıllık Değişim	-99.98%
5 Yıllık Değişim	-99.89%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

Hissedar Getirileri

	VBIV.Q	US Biotechs	US Pazar
7D	-1.2%	-0.2%	-0.4%
1Y	-97.2%	22.1%	34.1%

Getiri vs. Endüstri: VBIV.Q underperformed the US Biotechs industry which returned 21.7% over the past year.

Getiri vs Piyasa: VBIV.Q underperformed the US Market which returned 33.4% over the past year.

Fiyat Oynaklığı

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	53.7%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: VBIV.Q's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: VBIV.Q's weekly volatility has increased from 29% to 54% over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	135	Jeff Baxter	www.vbivaccines.com

Ticari aşamada bir biyofarmasötik şirketi olan VBI Vaccines Inc. immüno-onkoloji ve bulaşıcı hastalıkları tedavi etmek için aşılar geliştirmekte ve satmaktadır. Hepatit B (HBV) aşısını PreHevbrio, PreHevbri ve Sci-B-Vac markaları altında sunmaktadır. Şirket ayrıca, kronik HBV enfeksiyonunun tedavisi için protein bazlı bir immünoterapötik adayı olan VBI-2601; bir glioblastoma kanser aşısı immünoterapötik adayı olan VBI-1901; profilaktik bir sitomegalovirüs aşısı adayı olan VBI-1501 ve Zika virüsünü tedavi etmek için VBI-2501 geliştirmektedir.

VBI Vaccines Inc. Temel Bilgiler Özeti

VBI Vaccines'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VBIV.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$487.60k
Kazançlar(TTM)	-US$83.99m
Gelir(TTM)	US$9.41m

0.1x

P/S Oranı

0.0x

F/K Oranı

VBIV.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VBIV.Q gelir tablosu (TTM)
Gelir	US$9.41m
Gelir Maliyeti	US$11.67m
Brüt Kâr	-US$2.26m
Diğer Giderler	US$81.73m
Kazançlar	-US$83.99m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.93
Brüt Marj	-24.03%
Net Kâr Marjı	-892.47%
Borç/Özkaynak Oranı	-891.6%

VBIV.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VBIV.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

VBI Vaccines Inc. Rakipler

OTCPK:TCON

US$357.8k

OTCPK:IMPL.Q

US$358.5k

NasdaqCM:CYCC

US$2.0m

OTCPK:THER

US$615.1k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

Recent updates

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat